💊 Biocon Bets Big on Biosimilars & Semaglutide for Global Growth

Biocon is accelerating its global expansion strategy, focusing on market-share gains in biosimilars and preparing a multi-country rollout of semaglutide, one of the fastest-growing GLP-1 drug segments worldwide. Incoming group head Shreehas Tambe said strong demand and prioritisation of high-margin markets lifted biosimilars EBITDA margins to 28%. The company is scaling products such as aflibercept, ustekinumab, bevacizumab, denosumab, and insulin aspart across global markets. Biocon plans to commercialize semaglutide directly in Brazil, Canada, and the Middle East, while using partnerships in India as patents begin expiring from 2026. With major capex largely complete and clinical costs expected to fall due to regulatory changes, the company is entering a margin-expansion phase driven by operating leverage. 📌 StockYard Take: Biocon is shifting from heavy investment mode to a multi-year profit growth cycle backed by global biosimilars and GLP-1 opportunities. #Biocon #PharmaStocks #Biosimilars #GLP1 #GlobalExpansion #StockYardResearch